medline.ch Urologie-Nephrologie Tumoren BPH

	Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: YUSHIMA Study. Int J Urol Yasuda Y, Numao N, Matsumoto S, Tamiya T, Nakamura Y, Tanaka H, Yoshida S, Kobayashi S, Takazawa R, Matsuoka Y, Yonese J, Fujii Y. PMID: 40524477 [PubMed - as supplied by publisher]
	Assessing the frequency and accuracy of morphologic changes of focal bone lesions on [(68)Ga]Ga-PSMA-11 PET/CT in prostate cancer. Eur J Nucl Med Mol Imaging Sivakumar T, Heimer J, Beintner-Skawran S, Muehlematter UJ, Messerli M, Spielhofer N, Eberli D, Huellner MW, Burger IA, Maurer A. PMID: 40523941 [PubMed - as supplied by publisher]
	Response to Chen et al. "Comment on "Assessing the Diagnostic Metrics of Cutaneous Leiomyomas in Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Syndrome: An Observational Study". J Am Acad Dermatol Ouchene L, Udupa M, Mija LA, Moussa S, Fu L, Chergui M, Watters KA, Marino TC, Tanguay S, Brimo F, Rahme E, Kaouache M, Foulkes WD, Netchiporouk E. PMID: 40523440 [PubMed - as supplied by publisher]
	Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial. Lancet Oncol Agarwal N, Azad AA, Carles J, Matsubara N, Oudard S, Saad F, Merseburger AS, Soares A, McGregor BA, Zurawski B, Tsiatas M, North S, Bondarenko I, Alfie M, Bournakis E, Antonuzzo L, Evilevitch L, Simmons A, Wang F, Ferraldeschi R, Nandoskar P, Pal SK. PMID: 40523369 [PubMed - as supplied by publisher]
	Neoadjuvant Radiotherapy Combined with Transurethral Photoselective Vaporization of Bladder Tumors and Postoperative Adjuvant Radiotherapy and Chemotherapy for T3 Muscle-Invasive Bladder Cancer: A Retrospective Case Series Study. Photobiomodul Photomed Laser Surg Chen Y, Luo F, Li J, Zhang T. PMID: 40523218 [PubMed - as supplied by publisher]
	Identification of DCAF5 as a novel cancer prognostic and immunotherapy biomarker through pan-cancer analysis and renal clear cell carcinoma clinical data validation. Discov Oncol Yan H, Zhang L, Xu F, Chen T, Li R. PMID: 40522583 [PubMed]
	A real-world pharmacovigilance study of belzutifan in renal cell carcinoma and von Hippel-Lindau disease: insights from the FDA adverse event reporting system database. Int J Clin Pharm Ye Y, Fan B, Hu X. PMID: 40522401 [PubMed - as supplied by publisher]
	Effect of sex on adverse in-hospital outcomes after radical cystectomy according to urinary diversion type. World J Urol Rodriguez Peñaranda N, Di Bello F, Marmiroli A, Falkenbach F, Longoni M, Le QC, Goyal JA, Tian Z, Saad F, Shariat SF, Longo N, De Cobelli O, Graefen M, Briganti A, Chun FKH, Puliatti S, Micali S, Karakiewicz PI. PMID: 40522337 [PubMed - indexed for MEDLINE]
	The importance of maximal TURBT in trimodality therapy for muscle-invasive bladder cancer (MIBC). Bladder Cancer Wong CH, Ko IC, Leung DK, Siu B, Yuen SK, Teoh JY. PMID: 40521237 [PubMed]
	ABCG1 promotes the proliferation and migration of clear cell renal cell carcinoma and reduces its apoptosis. Int J Med Sci Dong Y, Qiao Q, Guo S, Chen R, Lin T, Liu X, Li J, Liu S, Jiang H, Wang Y, Yue D, Wang R. PMID: 40520894 [PubMed - indexed for MEDLINE]
	Associations Between Long-Term Exposure to Air Pollutants and Prostate Cancer in a Large Taiwanese Population. Int J Med Sci Geng JH, Li CY, Wu MT, Chen SC, Huang SP. PMID: 40520887 [PubMed - indexed for MEDLINE]
	Causal impact of genetically determined metabolites on kidney cancer and its subtypes: an integrated mendelian randomization and metabolomic study. Am J Cancer Res Wang Z, Huangfu Z, Liu T, Li Y, Gao Y, Gan X, Wu X, Chen S, Li X, Wang L, Gao X. PMID: 40520855 [PubMed]
	Advances in research regarding epithelial-mesenchymal transition and prostate cancer. Front Cell Dev Biol Wei X, Liu R, Li W, Yu Q, Yang QT, Li T. PMID: 40519259 [PubMed]
	[Recommendations for the management of kidney cancer in 2025]. Rev Med Liege Wick M, Denis C, Frères P, Sautois B, Waltregny D, Gennigens C. PMID: 40518885 [PubMed - indexed for MEDLINE]
	Risk-adapted intensification therapy in high-risk prostate cancer: how relevant is the role of radiation dose. Radiat Oncol Zapatero A, Roch M, Martín de Vidales C, Castro P, Montes N, Cruz Conde A, Fernández-Banda L, Zaragoza L, Carroceda S, García Vicente F. PMID: 40518535 [PubMed - indexed for MEDLINE]
	Comprehensive assessment of lower limb edema and its association with quality of life among men with prostate cancer. Support Care Cancer Jensen S, Røder A, Hayes S, Larsen GS, Fode M, Østergren PB, Al-Hamadani MMN, Johansen C, Rafn BS. PMID: 40518468 [PubMed - indexed for MEDLINE]
	Stereotactic Body Radiation Therapy for Primary Renal Cancer and Genetic Markers of Response: A Phase 2 Trial. Eur Urol Oncol Song C, Sung CO, Kim D, Kim Y, Ahn H, Kim MH, Kim JK, Cho YM, Kim YJ, Kim YS. PMID: 40518369 [PubMed - as supplied by publisher]
	Comment on "Assessing the Diagnostic Metrics of Cutaneous Leiomyomas in Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Syndrome: an Observational Study". J Am Acad Dermatol Qi M, Wang W, Xie Y, Li Y, Yang X. PMID: 40518119 [PubMed - as supplied by publisher]
	Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol Tree AC, Hinder V, Chan A, Tolan S, Ostler P, van der Voet H, Kancherla K, Loblaw A, Naismith O, Jain S, Martin A, Price D, Brand D, Chu W, Duffton A, Kelly P, O'Neill B, Staffurth J, Sasso G, Pugh J, Manning G, Brown S, Burnett S, Griffin C, Hall E, van As N, PACE Investigators. PMID: 40517778 [PubMed - as supplied by publisher]
	Node-RADS 1.0 for lymph node involvement detection in renal cell carcinoma: A study on 2D and 3D CT imaging. Eur J Radiol He C, Yuan E, Ye L, Xu H, Wu Q, Yao J, Chen Y, Song B. PMID: 40517517 [PubMed - as supplied by publisher]

Artikel 1 - 20 / 177301

Seite 1 von 8866



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung